Pure Global AI
NCT06221605Not yet recruiting

Regulation of Intestinal Flora by Compound Probiotics in Patients With Chronic Hepatitis B

Regulation of Intestinal Flora by Compound Probiotics in Patients With Chronic Hepatitis B: a Randomized, Double-blind, Placebo-controlled Study
Wecare Probiotics Co., Ltd.ClinicalTrials.govdietary supplement
Verified
Study focus
Disease/Condition
Chronic Hepatitis B
Drug/Device/Intervention
Probiotic
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Wecare Probiotics Co., Ltd.
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2024
End date
Apr 01, 2025
Enrollment
100 participants
Primary outcome

Test the level of HBV infection in chronic hepatitis B patients

Summary

The goal of this is to verify the clinical efficacy of compound probiotics in reducing HBV
 infection levels and regulating intestinal flora in patients with chronic hepatitis B.
 
 The main question it aims to answer is:
 
 • Conventional antiviral therapy combined with a 6-month probiotic intervention was used to
 evaluate the clinical efficacy of reducing HBV infection levels (HBeAg, HBsAg, and HBV DNA
 levels) and regulating gut microbiota.

ICD-10 classifications
Acute hepatitis BChronic viral hepatitis B without delta-agentAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agent : other and unspecified phaseChronic viral hepatitis B without delta-agent : immune-tolerant phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06221605
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06221605 through Pure Global AI's free database. This phase not specified trial is sponsored by Wecare Probiotics Co., Ltd. and is currently Not yet recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.